Positron (POSC) and The Competition Head-To-Head Review

Positron (OTCMKTS:POSC) is one of 74 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its rivals? We will compare Positron to similar businesses based on the strength of its dividends, institutional ownership, analyst recommendations, valuation, risk, earnings and profitability.

Profitability

This table compares Positron and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Positron	-300.00%	N/A	-89.57%
Positron Competitors	-331.31%	-92.24%	-30.04%

Earnings & Valuation

This table compares Positron and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Positron	$740,000.00	-$1.64 million	-12.13
Positron Competitors	$1.00 billion	$85.30 million	5.55

Positron’s rivals have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Positron has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Positron’s rivals have a beta of 17.00, indicating that their average share price is 1,600% more volatile than the S&P 500.

Institutional & Insider Ownership

44.1% of shares of all “Electromedical equipment” companies are held by institutional investors. 17.2% of Positron shares are held by company insiders. Comparatively, 14.8% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Positron and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Positron	0	0	0	0	N/A
Positron Competitors	270	803	2020	109	2.61

As a group, “Electromedical equipment” companies have a potential upside of 3,351.31%. Given Positron’s rivals higher possible upside, analysts plainly believe Positron has less favorable growth aspects than its rivals.

Summary

Positron rivals beat Positron on 7 of the 10 factors compared.

Positron Company Profile

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.